Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03545126 · ClinicalTrials.gov registry record
Human CNS Tau Kinetics in Tauopathies
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 27
- Enrollment target
NCT03545126: Completed study, sponsored by Washington University School of Medicine.
NCT03545126 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03545126 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS and to test the hypothesis that tau kinetics are altered (i.e. increased production, decreased clearance, and increased aggregation rate) in tauopathies.
Primary Outcome
Calculated by using CSF tau labeling and plasma free leucine.
Interventions
- OTHER 13C6 Leucine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-08-21 |
| Est. Completion | 2022-03-04 |
What the finished NCT03545126 record still lists
NCT03545126 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which 13C6 Leucine is the first listed.
NCT03545126 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03545126 about?
NCT03545126 is a clinical study titled "Human CNS Tau Kinetics in Tauopathies". The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS and to test the hypothesis that tau kinetics are altered (i.e. increased production, decreased clearance, and increased aggregation rate) in tauopathies.
What is the current status of trial NCT03545126?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2017-08-21. Estimated completion is 2022-03-04.
What interventions are being tested in trial NCT03545126?
The interventions under investigation include: 13C6 Leucine (OTHER).
Who is sponsoring clinical trial NCT03545126?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI